Abstract
The Coronavirus disease 2019 (COVID-19) has found its roots from Wuhan (China). COVID-19 is caused by a novel coronavirus SARS-CoV2, previously named as 2019-nCoV. It has spread across the globe and was declared as a pandemic by the World Health Organization (WHO) on 11th March, 2020. Currently, there is no standard drug or vaccine available for the treatment, therefore, repurposing of existing drugs is the only solution. Novel Drug Delivery Systems (NDDS) will be boon for the repurposing of drugs. The role of various NDDS in repurposing of existing drugs for the treatment of various viral diseases and their relevance in COVID-19 has been discussed in this paper. It focuses on the currently ongoing research in the implementation of NDDS in COVID-19. Moreover, it describes the role of NDDS in vaccine development for COVID-19. This paper also emphasizes how NDDS will help to develop the improved delivery systems (dosage forms) of existing therapeutic agents and also explore the new insights to find out the void spaces for potential targeted delivery. Therefore, in these tough times, NDDS and nanotechnology can be a safeguard to humanity.
Keywords: Anti-viral, COVID-19, nanoparticles, novel drug delivery system, repurposing, vaccine.
[http://dx.doi.org/10.1186/s40249-020-00646-x] [PMID: 32183901]
[http://dx.doi.org/10.5582/ddt.2020.01012] [PMID: 32147628]
[http://dx.doi.org/10.1097/JCMA.0000000000000270] [PMID: 32134861]
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105932] [PMID: 32145363]
[http://dx.doi.org/10.1083/jcb.102.3.959] [PMID: 3949884]
[http://dx.doi.org/10.1002/phar.2403] [PMID: 32281114]
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[http://dx.doi.org/10.1016/j.lfs.2020.117477] [PMID: 32119961]
[http://dx.doi.org/10.1182/bloodadvances.2020001907] [PMID: 32243501]
[http://dx.doi.org/10.1056/NEJMoa2001282] [PMID: 32187464]
[http://dx.doi.org/10.5582/bst.2020.01020] [PMID: 31996494]
[http://dx.doi.org/10.1128/AAC.49.3.981-986.2005] [PMID: 15728892]
[http://dx.doi.org/10.1016/j.eng.2020.03.007] [PMID: 32346491]
[http://dx.doi.org/10.1073/pnas.2005615117] [PMID: 32350134]
[http://dx.doi.org/10.1007/s11684-020-0767-8] [PMID: 32240462]
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949] [PMID: 32205204]
[http://dx.doi.org/10.1186/s13054-020-2818-6] [PMID: 32178711]
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[http://dx.doi.org/10.1074/jbc.M116.716100] [PMID: 26953343]
[http://dx.doi.org/10.1016/j.jinf.2020.03.060] [PMID: 32283143]
[http://dx.doi.org/10.1002/ptr.6024] [PMID: 29356205]
[http://dx.doi.org/10.4103/2231-4040.101007] [PMID: 23057001]
[http://dx.doi.org/10.2174/1567201052772915] [PMID: 16305405]
[http://dx.doi.org/10.4103/2231-4040.79802] [PMID: 22171289]
[http://dx.doi.org/10.1016/S1773-2247(09)50035-4]
[http://dx.doi.org/10.1016/S0076-6879(05)91020-3] [PMID: 15721391]
[http://dx.doi.org/10.1016/j.ijpharm.2005.10.010] [PMID: 16303268]
[http://dx.doi.org/10.1631/jzus.B0820047] [PMID: 18543406]
[http://dx.doi.org/10.1007/s11095-008-9615-2] [PMID: 18516666]
[http://dx.doi.org/10.1007/s00396-018-4304-0]
[http://dx.doi.org/10.1007/s00396-019-04552-z]
[http://dx.doi.org/10.1038/s41598-017-00200-0] [PMID: 28273907]
[http://dx.doi.org/10.1080/10611860600965914] [PMID: 17365278]
[http://dx.doi.org/10.1111/cei.13287] [PMID: 30963549]
![Wayfinder Image](/images/wayfinder.jpg)